Eli Lilly and Company (LLY) – Investment Analysts’ Recent Ratings Updates

Eli Lilly and Company (NYSE: LLY) recently received a number of ratings updates from brokerages and research firms:

• 11/2/2026 – Eli Lilly and Company had its price target raised by Cantor Fitzgerald from $1,440.00 to $1,600.00. They now have an “overweight” rating on the stock.
• 10/31/2026 – Eli Lilly and Company was upgraded by Wall Street Zen from “hold” to “buy”.
• 10/30/2026 – Eli Lilly and Company was downgraded by Weiss Ratings from “buy (b+)” to “buy (b)”.
• 10/30/2026 – Eli Lilly and Company had its price target raised by Argus from $1,300.00 to $1,550.00. They now have a “buy” rating on the stock.
• 10/30/2026 – Eli Lilly and Company had its price target raised by UBS Group from $1,425.00 to $1,625.00. They now have a “buy” rating on the stock.
• 10/30/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by BMO Capital Markets. They now have a $1,650.00 price target on the stock.
• 10/30/2026 – Eli Lilly and Company had its “buy” rating reaffirmed by Bank of America. They now have a $1,497.00 price target on the stock.
• 10/30/2026 – Eli Lilly and Company had its price target raised by Wells Fargo & Company from $1,330.00 to $1,500.00. They now have an “overweight” rating on the stock.
• 10/30/2026 – Eli Lilly and Company had its “buy” rating reaffirmed by Truist Financial. They now have a $1,612.00 price target on the stock, up from $1,376.00.
• 10/30/2026 – Eli Lilly and Company had its price target raised by JPMorgan Chase & Co. from $1,500.00 to $1,650.00. They now have an “overweight” rating on the stock.
• 10/30/2026 – Eli Lilly and Company had its price target raised by Citigroup from $1,600.00 to $1,650.00. They now have a “buy” rating on the stock.
• 10/30/2026 – Eli Lilly and Company had its price target raised by Scotiabank from $1,300.00 to $1,605.00. They now have a “sector outperform” rating on the stock.
• 10/30/2026 – Eli Lilly and Company had its price target raised by Morgan Stanley from $1,430.00 to $1,596.00. They now have an “overweight” rating on the stock.
• 10/30/2026 – Eli Lilly and Company had its price target raised by Royal Bank Of Canada from $1,500.00 to $1,600.00. They now have an “outperform” rating on the stock.
• 10/26/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by Sanford C. Bernstein. They now have a $1,450.00 price target on the stock.
• 10/21/2026 – Eli Lilly and Company had its price target raised by Leerink Partners from $1,309.00 to $1,316.00. They now have an “outperform” rating on the stock.
• 10/20/2026 – Eli Lilly and Company had its “buy” rating reaffirmed by The Goldman Sachs Group. They now have a $1,413.00 price target on the stock.
• 10/17/2026 – Eli Lilly and Company was downgraded by Wall Street Zen from “buy” to “hold”.
• 10/15/2026 – Eli Lilly and Company was upgraded by Weiss Ratings from “buy (b)” to “buy (b+)”.
• 10/12/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $1,500.00 price target on the stock.
• 10/8/2026 – Eli Lilly and Company had its price target raised by Cantor Fitzgerald from $1,410.00 to $1,440.00. They now have an “overweight” rating on the stock.
• 10/7/2026 – Eli Lilly and Company had its price target raised by Morgan Stanley from $1,419.00 to $1,430.00. They now have an “overweight” rating on the stock.
• 10/1/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by BMO Capital Markets.
• 9/28/2026 – Eli Lilly and Company had its price target raised by JPMorgan Chase & Co. from $1,400.00 to $1,500.00. They now have an “overweight” rating on the stock.
• 9/22/2026 – Eli Lilly and Company had its “buy” rating reaffirmed by TD Cowen. They now have a $1,250.00 price target on the stock.
• 9/18/2026 – Eli Lilly and Company had its price target raised by Guggenheim from $1,273.00 to $1,284.00. They now have a “buy” rating on the stock.
• 9/17/2026 – Eli Lilly and Company had its price target raised by The Goldman Sachs Group from $1,367.00 to $1,371.00. They now have a “buy” rating on the stock.
• 9/15/2026 – Eli Lilly and Company was upgraded by Berenberg Bank from “hold” to “buy”. They now have a $1,400.00 price target on the stock.
• 9/15/2026 – Eli Lilly and Company was upgraded by Berenberg Bank from “hold” to “buy”. They now have a $1,400.00 price target on the stock.
• 9/10/2026 – Eli Lilly and Company had its price target raised by HSBC from $850.00 to $940.00. They now have a “reduce” rating on the stock.
• 9/9/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by BMO Capital Markets.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY traded up $8.76 on Wednesday, reaching $1,418.14. 3,632,414 shares of the company’s stock were exchanged, compared to its average volume of 2,950,898. The company has a fifty day moving average of $1,204.03 and a 200-day moving average of $1,095.92. Eli Lilly and Company has a twelve month low of $850.51 and a twelve month high of $1,449.68. The company has a market capitalization of $1.33 trillion, a price-to-earnings ratio of 46.03, a PEG ratio of 1.77 and a beta of 0.40. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, topping the consensus estimate of $5.71 by $1.77. The company had revenue of $24.40 billion for the quarter, compared to analysts’ expectations of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The business’s revenue for the quarter was up 38.6% on a year-over-year basis. During the same period last year, the firm earned $7.02 earnings per share. On average, research analysts predict that Eli Lilly and Company will post 35.61 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is 22.46%.

Insider Buying and Selling at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 2,000 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the transaction, the chief accounting officer owned 1,526 shares in the company, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the transaction, the executive vice president owned 4,137 shares in the company, valued at $5,802,225.24. The trade was a 54.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 18,500 shares of company stock valued at $22,970,770 in the last three months. Corporate insiders own 0.14% of the company’s stock.

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.